In this study, we also demonstrated that LAT2 played an oncogenic role in pancreatic cancer and could decrease GEM sensitivity by regulating the glutamine-dependent LAT2-mTOR-LDHB pathway. This evidence concerns the gene LAT2 and familial pancreatic carcinoma.